Saniona AB (publ) (STO:SANION)
Sweden
· Delayed Price · Currency is SEK | Market Cap | 1.93B |
| Revenue (ttm) | 434.40M |
| Net Income (ttm) | 284.67M |
| Shares Out | 138.03M |
| EPS (ttm) | 2.15 |
| PE Ratio | 6.51 |
| Forward PE | 34.14 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 375,027 |
| Average Volume | 567,211 |
| Open | 14.10 |
| Previous Close | 14.03 |
| Day's Range | 13.81 - 14.33 |
| 52-Week Range | 7.01 - 28.30 |
| Beta | 1.28 |
| RSI | 35.79 |
| Earnings Date | May 26, 2026 |
About Saniona AB
Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company’s product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical trial to treat people with obesity; and Tesomet, an oral investigational therapy, which is in Phase 2b clinical trial for the treatment of hypothalamic ... [Read more]
Financial Performance
In 2025, Saniona AB's revenue was 434.40 million, an increase of 29.80% compared to the previous year's 334.67 million. Earnings were 284.67 million, an increase of 50.85%.
Financial StatementsNews
Saniona AB Transcript: Life Science Conference 2026
Major licensing deals with Acadia and Jazz have strengthened financials and enabled a robust internal pipeline targeting CNS diseases. Multiple clinical programs are advancing, with near-term milestones expected and a strategy focused on both internal development and strategic partnerships.
Saniona AB (FRA:30S) Q4 2025 Earnings Call Highlights: Strategic Partnerships and Financial ...
Saniona AB (FRA:30S) Q4 2025 Earnings Call Highlights: Strategic Partnerships and Financial Challenges
Q4 2025 Saniona AB Earnings Call Transcript
Q4 2025 Saniona AB Earnings Call Transcript
Saniona AB Transcript: Life Science-dagen 2026
Strong cash reserves and major partnerships support advancement of three internal CNS programs into clinical trials, with phase I readouts expected in 2027. Selective GABA modulators target high unmet needs in epilepsy and depression, aiming for rapid growth and future phase III readiness.
Saniona AB (FRA:30S) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Financial ...
Saniona AB (FRA:30S) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Financial Strength Propel Growth
Q3 2025 Saniona AB Earnings Call Transcript
Q3 2025 Saniona AB Earnings Call Transcript
Saniona AB Transcript: Life Science Summit 2025
Strong financials and major partnerships support a robust CNS pipeline, with multiple assets advancing toward clinical trials in epilepsy and depression. The company targets large markets and aims for broad regulatory labels, leveraging recent high-value industry deals.
Saniona AB Transcript: Status Update
Strategic focus is on advancing ion channel programs and Tesofensine, supported by a strong financial position from the Acadia deal. Anticipated milestones include Tesofensine approval in Mexico, expansion into new markets, and progress in research collaborations, with a commitment to financial discipline.